View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)
-
Invivyd (IVVD) Announces PEMGARDA Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
-
Invivyd, Inc. (IVVD) Misses Q2 EPS by 3c
-
Invivyd (IVVD) Announces its Addition to the Russell 2000 and Russell 3000 Indexes
-
Invivyd (IVVD) Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
